Technical University of Denmark



A tropical tale: how Naja nigricollis venom beats Trypanosoma brucei

Martos Esteban, Andrea; Laustsen, Andreas Hougaard; Carrington, Mark

Publication date: 2016

Document Version Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

Martos Estebán, A., Laustsen, A. H., & Carrington, M. (2016). A tropical tale: how Naja nigricollis venom beats Trypanosoma brucei. Poster session presented at Symposium for Biological and Life Science Students (SymBLS) 2016, Cambridge, United Kingdom.

DTU Library Technical Information Center of Denmark

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.

- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



A tropical tale: how Naja nigricollis venom beats Trypanosoma brucei


Andrea Martos Esteban¹, Andreas Hougaard Laustsen¹, Mark Carrington²

¹Department of Biotechnology and Biomedicine, Technical University of Denmark ²Department of Biochemistry, University of Cambridge

have

Sleeping sickness: a neglected tropical disease

Trypanosoma brucei is a parasitic protozoan species capable to infecting insect vectors whose bite further produces African sleeping sickness in human beings [1]. During the parasite's extracellular life in the mammalian host, its outer coat, mainly composed of Variable Surface Glycoproteins (VSGs) [2] undergoes enormous variation in its composition to avoid the host's lytic



A tropical tale of trypanosomes and snakes

The elapid *N. nigricollis* is a Unknown Venom composition Nawaprin large venomous snake Minor CRISP from sub-Saharan Africa [4]. components P-III snake venom metaloproteinase PLA_2 the origin of Since Endonuclease Type I α neurotoxin-like pharmacology, venoms Muscarine toxin-like been used as medicines, since venom toxins target a myriad of Cytotoxin-like different physiological with high processes


UNIVERSITY OF CAMBRIDGE

immune response [3].

N. nigricollis venom is able to kill T. brucei by targeting GPI anchoring of VSG

Phospholipases A_2 are one of the major enzymatically active components in *N. nigricollis* venom, which could be targeting the GPI anchor of VSG. Lyophilized whole venom was diluted in HMI-9 cell culture media, in which we cultured *T. brucei* parasites expressing eGFP attached to GPI (VSG121) with 10 µm/ml of N. nigricollis venom during 24 hours. Then, we study the surveillance and the GFP-GPI release by flow cytometry.

Parasite cells counts by flow cytometry




PLA₂ and cytotoxins are potentially the toxins responsible of the parasite death

After gel filtration of 20 mg of N. nigricollis whole venom, we tested

specificity and selectivity.

N. nigricollis venom provokes the flagellar pocket enlargement by accumulating GPI

We observed VSG121 parasites using the fluorescence microscope. Contrarily to the parasites' phenotype during venom absence, parasites cultured with the N. nigricollis venom show a greener and enlarged flagellar pocket over the time.




Impact

I. First report of using snake venom to effectively kill effectively T. brucei.



each venom fraction in culture and ran a SDS-PAGE, which was developed by silver-staining.



References

[1] Kennedy PG E., 2013. The Lancet. DOI:10.1016/S1474-4422(12)70296-X. [2] Sunter J., et al. 2013. PLOS Pathogen. DOI:10.1371/journal.ppat.1003566. [3] Fenn K. and Matthews K R., 2007. Current Opinion in Microbiology. DOI:10.1016/j.mib.2007.09.014. [4] Petras D., et al. 2011. Journal of Proteome Research. DOI:10.1021/pr101040f

II. Novel molecular target antigenic allowing variation-independent, to bypass the main challenge of developing a successful treatment for the neglected tropical disease, African sleeping sickness.

III. Unveiling of the mechanism of parasite lethality may help pave the way for novel molecular tools for drug discovery against trypanosome related diseases.

Contact information

kDa

250

75

50

37

20

DTU Biotechnology and Biomedicine Technical University of Denmark Søltofts Plads 223 – 2800 – Kgs. Lyngby, Denmark andrea.martos.esteban@gmail.com / (+34) 676 181 350

Acknowledgements

We thank the Novo Nordisk Foundation (NNF16OC0019248), Symphogen A/S and Otto Mønsted Fond for financial support.